within Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BB08_Revefenacin;

model Revefenacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 0.0001961111111111111,
    adminDuration = 600,
    adminMass = 175 / 1000000,
    adminCount = 1,
    Vd = 0.218,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 2.7,
    k12 = 0.00019138888888888892,
    k21 = 0.00019138888888888892);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Revefenacin</td></tr><tr><td>ATC code:</td><td>R03BB08</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>175</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>218</td><td>L</td></tr>
    <tr><td>clearance:</td><td>706</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Revefenacin is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is administered via oral inhalation and is approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from clinical studies in adult patients with COPD following inhalation of revefenacin.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03BB08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Revefenacin;
